Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMU-838 (vidofludimus calcium) in progressive multiple sclerosis
2021-000048-23Phase 2Active
- Sponsor
- Immunic Therapeutics
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in progressive multiple sclerosis (PMS) comparing IMU-838 with Placebo (2 arms). Primary endpoint: Annualized rate of percent brain volume change. Started Aug 2021; status: active.
02
Drugs
vidofludimus calcium
03
Conditions
progressive multiple sclerosis (PMS)
Beyond the preview
Go deeper on 2021-000048-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000048-23.